Menu
Search

News

Swiss Deep Tech News & Analysis

Stay informed on the Swiss technology landscape. This is your central resource for Deep Tech News, combining key developments from across the ecosystem with original, data-driven analysis from the Deep Tech Nation Foundation. We track and report on significant technological milestones, funding rounds, and research to provide a comprehensive overview for international investors, partners, and researchers.

Curated Newsfeed

See all news

DTN Highlights

See DTN Highlights

  • Tech Tour Growth Top 50 showcases Swiss deeptech companies

    Switzerland is a hub of innovation, home to numerous trailblazing startups, including six that have earned a spot in the Tech Tour Growth Top 50…

    startupticker.ch

    • Six Swiss startups made the 2025 Tech Tour Growth50 list, with four securing over $20 million in funding.
    • Swiss companies like ANYbotics, Lakera AI, and DistalMotion lead in robotics, AI security, and surgical innovation.
    • International investors increasingly fund European tech leaders, challenging US dominance in attracting global investment.
    startupticker.ch: Tech Tour Growth Top 50 showcases Swiss deeptech companies

  • BioVersys to go public at SIX Swiss Exchange

    BioVersys develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant bacteria. The Basel-based company plans to conduct an initial public offering on the…

    startupticker.ch

    • BioVersys plans Q1 2025 IPO on SIX Swiss Exchange, targeting CHF 80M for BV100 Phase 3 development.
    • BV100 treats carbapenem-resistant Acinetobacter baumannii (50% mortality); Alpibectir targets TB.
    • GSK and AMR Action Fund, existing shareholders, committed to additional IPO investment.
    startupticker.ch: BioVersys to go public at SIX Swiss Exchange

  • Swiss startups strengthen presence in North America

    With the establishment of their new offices in the US, Attolight, Blocksport and NewBiologix, aim to increase proximity to customers in the North American market,…

    startupticker.ch

    • Attolight, Blocksport, and NewBiologix opened U.S. offices to expand customer relationships and North American market presence.
    • Blocksport launched a New York hub for sports fan engagement platforms and digital collectibles for North American clubs.
    • NewBiologix formed a U.S. subsidiary offering gene and cell therapy support, including its Xcell Portfolio for viral vector analysis.
    startupticker.ch: Swiss startups strengthen presence in North America

  • RhyGaze raises USD 86 million to advance gene therapy for retinal diseases

    Based in Basel and Philadelphia, USA, RhyGaze has secured a Series A financing of USD 86 million to enable clinical advancements for its lead candidate,…

    startupticker.ch

    • RhyGaze secured $86M Series A funding from Google Ventures for gene therapy to restore vision in blindness.
    • The technology aims to restore high-acuity vision by repairing cone cells in retinal diseases.
    • Funding supports preclinical testing, observational studies, and a first-in-human clinical trial.
    startupticker.ch: RhyGaze raises USD 86 million to advance gene therapy for retinal diseases

  • Sygnum achieves unicorn status with USD 58m growth round

    Global digital asset banking group Sygnum has raised a total of USD 58 million in its oversubscribed Strategic Growth Round, giving it a post-money valuation…

    startupticker.ch

    • Sygnum raised $58M in a strategic round, achieving unicorn status with $1B+ valuation and $5B in client assets.
    • Sygnum achieved profitability in 2024 with 1,000%+ YoY trade growth, driven by B2B partnerships serving over one-third of Switzerland.
    • Sygnum plans EU/EEA and Hong Kong expansion, focusing on Bitcoin products and strengthening compliance infrastructure.
    startupticker.ch: Sygnum achieves unicorn status with USD 58m growth round

  • Windward Bio launches with $200 million Series A financing round

    Founded by serial entrepreneur Luca Santarelli, Windward Bio has just launched with a $200 million capital injection. These funds will accelerate clinical advancements in programs…

    startupticker.ch

    • Windward Bio raised $200M Series A to develop WIN378, a monoclonal antibody for severe asthma and COPD dosed every six months.
    • WIN378 targets TSLP ligand to treat ~5M patients with advanced, uncontrolled asthma/COPD in US, Europe, and Japan.
    • Windward Bio's founding team contributed to 15+ product launches, 2 Nasdaq IPOs, and 2 strategic exits.
    startupticker.ch: Windward Bio launches with $200 million Series A financing round

  • ONWARD Medical wins first commercial customers in the US

    With the first commercial sale of the ARC-EX System in the US, ONWARD Medical has reached a key milestone in its journey to provide innovative…

    startupticker.ch

    • ONWARD Medical's ARC-EX System is FDA-approved to improve hand strength and sensation in spinal cord injury patients via electrical stimulation.
    • The device received FDA de novo classification on December 19, 2024, with first sales at UW Medicine and Next Steps Chicago.
    • ONWARD plans home use authorization in 2025, European CE Mark certification, and implantable alternatives including brain-computer interfaces.
    startupticker.ch: ONWARD Medical wins first commercial customers in the US

  • Numab raises additional CHF50 million

    Numab Therapeutics, a clinical stage biotechnology company focusing on multi-specific antibodies in immunology and oncology, closed an oversubscribed CHF 50 million Series C extension, bringing…

    startupticker.ch

    • Numab Therapeutics raised CHF 50 million in Series C extension funding, bringing total Series C to CHF 180 million.
    • Johnson & Johnson's 2024 acquisition of Numab spin-out Yellow Jersey for $1.25 billion validated the platform.
    • Funding will advance clinical and pre-clinical multi-specific antibodies for inflammation and oncology.
    startupticker.ch: Numab raises additional CHF50 million

  • CeQur secures $120 million to scale diabetes management solutions

    With more than 6000 patients using the injection-free insulin delivery device, CeQur Simplicity patch, Medtech company CeQur has secured fresh equity funding to further drive…

    startupticker.ch

    • CeQur Simplicity patch has over 6,000 patients and secured equity funding to expand commercial operations.
    • The patch replaces twelve daily injections over four days, with 90% of patients reporting better adherence.
    • Over 80% of claims covered as pharmacy benefit with average copay under $45/month; new facility starts 2025.
    startupticker.ch: CeQur secures $120 million to scale diabetes management solutions

  • Araris enters multi-million contract with Chugai

    Araris Biotech AG, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has entered a Research Collaboration and Option to License Agreement under…

    startupticker.ch

    • Araris Biotech partnered with Chugai Pharmaceutical on antibody-drug conjugates, with potential milestones up to USD 780 million plus royalties.
    • Araris' AraLinQ platform attaches multiple cancer-fighting payloads to antibodies in one step, improving safety, efficacy, and resistance.
    • This second major pharma collaboration validates the attractiveness of Araris' ADC platform technology.
    startupticker.ch: Araris enters multi-million contract with Chugai

  • Sonar to acquire Tidelift to reduce risk from open source software

    Geneva-based Sonar has signed a definitive agreement to acquire Tidelift, a provider of software supply chain security solutions that help organizations manage the risk of…

    startupticker.ch

    • Sonar acquired Tidelift to extend code security coverage to open source libraries, which comprise over 90% of software builds.
    • Paid open source maintainers are 55% more likely to implement critical security practices compared to unpaid maintainers.
    • Sonar's platform analyzes all code types—internal, AI-generated, and open source—across 30+ programming languages.
    startupticker.ch: Sonar to acquire Tidelift to reduce risk from open source software

  • SkyCell acquires majority stake in Dutch risk assessment and collaboration platform

    SkyCell, a global leader in safe, secure, and sustainable pharma supply chain solutions, has made a multimillion investment in Validaide. Based in the Netherlands, Validaide…

    startupticker.ch

    • SkyCell invested millions in Validaide, a Netherlands-based lane risk assessment platform used by over 1,600 companies.
    • Validaide will maintain operational independence and neutrality as a trusted platform for all pharma supply chain stakeholders.
    • SkyCell's investment enables Validaide to expand its tech team and develop faster lane approvals, advanced risk modeling, and emissions reporting.
    startupticker.ch: SkyCell acquires majority stake in Dutch risk assessment and collaboration platform